Last reviewed · How we verify
Uromune
At a glance
| Generic name | Uromune |
|---|---|
| Also known as | MV140 |
| Sponsor | Queen's University |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Protocol 19-01: Canadian, Single Centre, Pilot, Open Label Study to Evaluate the Efficacy and Safety of the Bacterial Vaccine Uromune in Treating Recurrent Urinary Tract Infections in Women. (Phase 2)
- Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI) (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uromune CI brief — competitive landscape report
- Uromune updates RSS · CI watch RSS
- Queen's University portfolio CI